#151837

Anti-TIMP2 [3A4]

Cat. #151837

Anti-TIMP2 [3A4]

Cat. #: 151837

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: TIMP2 (tissue inhibitor of metalloproteinases 2)

Class: Monoclonal

Application: IHC ; ELISA ; IHC ; WB

Reactivity: Human ; Mouse ; Rat ; Zebrafish

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Ayham Alnabulsi

Institute: Vertebrate Antibodies Limited

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-TIMP2 [3A4]
  • Research fields: Biochemistry;Cancer;Cell biology;Cell signaling and signal transduction;Tissue-specific biology
  • Clone: 3A4
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human ; Mouse ; Rat ; Zebrafish
  • Host: Mouse
  • Application: IHC ; ELISA ; IHC ; WB
  • Description: Matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix (ECM) in normal physiological processes as well as in disease processes. Tissue inhibitors of metalloproteinases (TIMPs) are the main physiological regulators of the MMPs. The TIMPs are secreted proteins that complex with individual MMPs and regulate the activity of specific MMPs. Together, the MMPs and TIMPs form a complex biological system strictly controlling degradation of ECM. The MMPs and TIMPs have a significant role in facilitating tumour invasion and metastasis. Expression of TIMP2 has been identified in individual studies as prognostic biomarkers in established and locally advanced colorectal cancer.
  • Immunogen: Ovalbumin-conjugated synthetic peptide; DSGNDIYGNPI
  • Isotype: IgG2b
  • Myeloma used: P3X63Ag8.653
  • Recommended controls: IHC: formalin-fixed, paraffin-embedded colonic adenocarcinoma Western blot: rhTIMP-2, 400 ng per lane

Target Details

  • Target: TIMP2 (tissue inhibitor of metalloproteinases 2)
  • Tissue cell line specificity: IHC: formalin-fixed, paraffin-embedded colonic adenocarcinoma Western blot: rhTIMP-2, 400 ng per lane
  • Target background: Matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix (ECM) in normal physiological processes as well as in disease processes. Tissue inhibitors of metalloproteinases (TIMPs) are the main physiological regulators of the MMPs. The TIMPs are secreted proteins that complex with individual MMPs and regulate the activity of specific MMPs. Together, the MMPs and TIMPs form a complex biological system strictly controlling degradation of ECM. The MMPs and TIMPs have a significant role in facilitating tumour invasion and metastasis. Expression of TIMP2 has been identified in individual studies as prognostic biomarkers in established and locally advanced colorectal cancer.

Applications

  • Application: IHC ; ELISA ; IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -80° C
  • Shipping conditions: Shipping at 4° C

References

  • Keren-Shaul et al. 2017. Cell. 169(7):1276-1290.e17. PMID: 28602351.
  • A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.
  • Jeffery et al. 2009. Histopathology. 54(7):820-8. PMID: 19635101.
  • The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers.
  • Lyall et al. 2006. Clin Cancer Res. 12(4):1184-91. PMID: 16489072.
  • Profiling markers of prognosis in colorectal cancer.
  • Curran et al. 2004. Clin Cancer Res. 10(24):8229-34. PMID: 15623598.
  • Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
  • Murray et al. 1998. Gut. 43(6):791-7. PMID: 9824606.
  • Matrix metalloproteinases and their inhibitors in gastric cancer.